The Board of Pharmacy has received notice of the following product recall:

Product Recall of QC Max Str Acid Reducer Tablets, Ranitidine 150mg, 24 count. **UPC # 6-35515-99643-4**

Product Recall of QC Max Str Acid Reducer Tablets, Ranitidine 150mg, 50 count. **UPC # 6-35515-99644-1**

Product Recall of QC Reg Str Acid Reducer Tablets, Ranitidine 75mg, 60 count. **UPC # 6-35515-99645-8**

Product Recall of QC Reg Str Acid Reducer Tablets, Ranitidine 75mg, 30 count. **UPC # 6-35515-99646-5**

CDMA is recalling the above product to the retail level. The supplier, Dr. Reddy's, is initiating a recall of Ranitidine products. This voluntary recall is being initiated based on USFDA alert notice regarding low levels of N-nitrosodimethylamine (NDMA) impurity found in some samples of Ranitidine medicines. Subsequent preliminary test results at Dr. Reddy’s laboratories for some of the Drug Substance (API) lots used in Drug Product manufacturing have levels of NDMA that could potentially contribute to elevated levels of NDMA in Drug Product with respect to the maximum allowable daily limit. **All lots will be affected.**

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.